| Molecular Formula | C19H17N5 |
| Molar Mass | 315.37 |
| Density | 1.17±0.1 g/cm3(Predicted) |
| Boling Point | 498.0±47.0 °C(Predicted) |
| Solubility | DMSO: ≥ 32 mg/mL |
| Appearance | powder |
| Color | white to beige |
| pKa | 4.52±0.12(Predicted) |
| Storage Condition | Keep in dark place,Sealed in dry,2-8°C |
| In vitro study | Pre-incubation with A-804598 (0.1-10 μM; 1 hour) significantly attenuates BzATP-induced cell loss in a concentration-dependent manner. 3 μM A-804598 exhibits the greatest protective effect against BzATP-induced cytotoxicity. Cell Cytotoxicity Assay Cell Line: microglial cell Concentration: 0.1, 0.3, 1, 3, 10 μM Incubation Time: 1 hour Result: Protected against BzATP-induced cytotoxicity in both inactivated and activated microglia. |
| In vivo study | A chroni treatment with A-804598 (intraperitoneal injection; 30 mg/kg; five times a week) decreases the expression of LC3B-II and SQSTM1/p62 in lumbar spinal cord at end stage of disease. Animal Model: Adult B6.Cg-Tg (SOD1-G93A) 1Gur/J female mice Dosage: 30 mg/kg Administration: Intraperitoneal injection; five times a week Result: Decreased SQSTM1/p62 expression. |
| Hazard Symbols | T - Toxic![]() |
| Risk Codes | 25 - Toxic if swallowed |
| Safety Description | 45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
| UN IDs | UN 2811 6.1 / PGIII |
| WGK Germany | 3 |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.171 ml | 15.854 ml | 31.709 ml |
| 5 mM | 0.634 ml | 3.171 ml | 6.342 ml |
| 10 mM | 0.317 ml | 1.585 ml | 3.171 ml |
| 5 mM | 0.063 ml | 0.317 ml | 0.634 ml |
| biological activity | A-804598 is a CNS penetrating, competitive and selective P2X7 receptor antagonist that acts in mice, the rat and human P2X7 receptors, IC50s, are 9 nM, 10 nM and 11 nM, respectively. |
| Target | IC50: 9 nM (mouse P2X7 receptor), 10 nM (rat P2X7 receptor), 11 nM (human P2X7 receptor) |
| in vitro study | Pre-incubation with A- 804598 (0.1-10 μm; 1 hour) significant attributes BzATP-induced cell loss in a concentration-dependent manner. 3 μm A- 804598 exhibits the great protective effect against BzATP-induced Cytoxicity. Cell cytotoxity Assay Cell Line: microglial cell Concentration: 0.1, 0.3, 1, 3, 10 μM Incubation Time: 1 hour Result: Protected against BzATP-induced cytotoxicity in both inactivated and activated microglia. |
| Cell Line: | microglial cell |
| Concentration: | 0.1, 0.3, 1, 3, 10 μM |
| Incubation Time: | 1 hour |
| Result: | Protected against BzATP-induced cytotoxicity in both inactivated and activated microglia. Decreased SQSTM1/p62 expression. |
| in vivo study | A pH treatment with A- 804598 (intraperone injection; 30 mg/kg; five times a week) the expression of LC3B-II and SQSTM1/p62 in lumbar spinal cord at end stage of disease. Animal Model: Adult B6.Cg-Tg (SOD1-G93A) 1Gur/J female mice Dosage: 30 mg/kg; five times a week Result: Decreased SQSTM1/p62 expression. |
| Animal Model: | Adult B6.Cg-Tg (SOD1-G93A) 1Gur/J female mice |
| Dosage: | 30 mg/kg |
| Administration: | Intraperitoneal injection; five times a week |